The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The role of the immune system is to recognize pathogens, tumor cells or dead cells and to react with a very specific and localized response. By taking advantage of a highly sophisticated system of chemokines and chemokine receptors, leukocytes such as neutrophils, macrophages, and T-lymphocytes are targeted to the precise location of inflammation. While this is a beneficial process for acute infection and inflammation, recruitment of immune cells to sites of chronic inflammation can be detrimental. It is becoming clear that these inflammatory cells play a significant role in the initiation and progression of metabolic disorders such as atherosclerosis and insulin resistance by infiltrating the artery wall and adipose tissue (AT), respectively. Data from human studies indicate that elevated plasma levels of chemokines are correlated with these metabolic diseases. Recruitment of macrophages to the artery wall is well known to be one of the first steps in early atherosclerotic lesion formation. Likewise, recruitment of macrophages to AT is thought to contribute to insulin resistance associated with obesity. Based on this knowledge, much recent work in these areas has focused on the role of chemokines in attracting immune cells (monocytes/macrophages in particular) to these 2 sites. Thus, understanding the potential for chemokines to contribute to metabolic disease can help direct studies of chemokines as therapeutic targets. In this article, we will review current literature regarding the role of chemokines in atherosclerosis and obesity-related insulin resistance. We will focus on novel work showing that chemokine secretion from endothelial cells, platelets, and adipocytes can contribute to immune cell recruitment, with a diagram showing the time course of chemokine expression and leukocyte recruitment to AT. We will also highlight a few of the less-commonly known chemokine-chemokine receptor pairs. Finally, we will discuss the potential for chemokines as therapeutic targets for treatment of atherosclerosis and insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.1964 · Cited by 2,230 · cited 4×
“The expression of other chemokines such as MIP-1α, MIP-1β, and RANTES is elevated at a later time point (12–16 weeks) and continues to be elevated through 26 wks of high fat diet feeding (Xu, H. et al., 2003; Jiao et al., 2009; Nishimura et al., 2009).”
BackgroundInfluentialFeuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J., Goldfine, A. B., Benoist, C., Shoelson, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.2002 · Cited by 2,145 · cited 1×
“Additional sources used: (Weisberg et al., 2003; Xu, H. et al., 2003; Caspar-Bauguil et al., 2005; Coenen et al., 2007; Strissel et al., 2007; Takahashi et al., 2007; Rausch et al., 2008; Duffaut et al., 2009a; Feuerer et al., 2009; Winer et al., 2009) Vascul Pharmacol.”
MethodHuman epicardial adipose tissue is a source of inflammatory mediators
Mazurek, T., Zhang, L., Zalewski, A., Mannion, J. D., Diehl, J. T., Arafat, H., Sarov-Blat, L., O’Brien, S., Keiper, E. A., Johnson, A. G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000099542.57313.c5 · Cited by 1,966 · cited 1×
“Human eAT has greater mRNA expression of inflammatory genes including numerous chemokines (MCP-1, MIP-1α, MIP-1β, RANTES, CCL11, CCL18, CCL21, CXCL1, CXCL2) and chemokine receptors (CCR2, CXCR4, CXCR6) as compared to sAT (Mazurek et al., 2003).”
BackgroundBoring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998) · Nature · doi:10.1038/29788 · Cited by 1,965 · cited 1×
“Two groups have demonstrated that mice deficient in both CCR2 and apoE (CCR2−/−;apoE−/− mice) have smaller aortic root lesions than apoE−/− control mice despite an absence of change in plasma lipids (Boring et al., 1998; Dawson et al., 1999).”
BackgroundCCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370 · cited 1×
“Additional sources used: (Weisberg et al., 2003; Xu, H. et al., 2003; Caspar-Bauguil et al., 2005; Coenen et al., 2007; Strissel et al., 2007; Takahashi et al., 2007; Rausch et al., 2008; Duffaut et al., 2009a; Feuerer et al., 2009; Winer et al., 2009) Vascul Pharmacol.”
MethodAdipocyte Death, Adipose Tissue Remodeling, and Obesity Complications
Strissel, K. J., Stancheva, Z., Miyoshi, H., Perfield, J. W., DeFuria, J., Jick, Z., Greenberg, A. S., & Obin, M. S. (2007) · Diabetes · doi:10.2337/db07-0767 · Cited by 1,007
Rausch, M. E., Weisberg, S., Vardhana, P., & Tortoriello, D. V. (2008) · International Journal of Obesity · doi:10.1038/sj.ijo.0803744 · Cited by 585
Kim, C.-S., Park, H.-S., Kawada, T., Kim, J.-H., Lim, D., Hubbard, N. E., Kwon, B.-S., Erickson, K. L., & Yu, R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803259 · Cited by 511 · cited 1×
“Recent studies have also shown that elevated plasma levels of chemokines such as MCP-1 and IL-8 are associated with obesity and its related metabolic abnormalities such as inflammatory cytokines and reduced high density lipoprotein levels (Kim et al., 2006).”
Background
Cited by
Roles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Obesity-Associated Oxidative Stress: Strategies Finalized to Improve Redox State
Savini, I., Catani, M., Evangelista, D., Gasperi, V., & Avigliano, L. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510497 · Cited by 503
Perivascular adipose tissue inflammation in vascular disease
Nosalski, R., & Guzik, T. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13705 · Cited by 398
Frydrych, L. M., Bian, G., O’Lone, D. E., Ward, P. A., & Delano, M. J. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5vmr0118-021rr · Cited by 299
Macrophage recruitment in obese adipose tissue
Bai, Y., & Sun, Q. (2015) · Obesity Reviews · doi:10.1111/obr.12242 · Cited by 280
Kraakman, M. J., Murphy, A. J., Jandeleit-Dahm, K., & Kammoun, H. L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00470 · Cited by 277
Handa, P., Tateya, S., Rizzo, N. O., Cheng, A. M., Morgan-Stevenson, V., Han, C.-Y., Clowes, A. W., Daum, G., O'Brien, K. D., Schwartz, M. W., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.236554 · Cited by 86
Yoshida, H., Watanabe, H., Ishida, A., Watanabe, W., Narumi, K., Atsumi, T., Sugita, C., & Kurokawa, M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.038 · Cited by 66
Altered release of chemokines by phagocytes from fibromyalgia patients: a pilot study
García, J. J., Carvajal-Gil, J., & Guerrero-Bonmatty, R. (2016) · Innate Immunity · doi:10.1177/1753425915602959 · Cited by 9
“Nevertheless, they may also attract neutrophils under certain conditions.(33) Based on the above, in our opinion increased functional activity of neutrophils in FM could well be due, at least in part, to the increased release of GRO-a, MDC and eotaxin by isolated monocytes from women with FM.”
Background
Metadata
- Authors
- Surmi, B. K., & Hasty, A. H.
- Venue
- Vascular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 52
- Issue
- 1-2
- Pages
- 27-36
- ISSN
- 1537-1891 (ISSN-L)
- OpenAlex
- W2065391775
- Cited by
- 129
- References
- 15
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.